Assessment of Glucose Disposal Rate Changes and the Onset of Cardiovascular Disease in Patients with Stages 0–3 of Cardiovascular–Kidney–Metabolic Syndrome: A Prospective Cohort Analysis from China - Scorecard - MDSpire
Advertisement
Assessment of Glucose Disposal Rate Changes and the Onset of Cardiovascular Disease in Patients with Stages 0–3 of Cardiovascular–Kidney–Metabolic Syndrome: A Prospective Cohort Analysis from China
Clinical Scorecard: Assessment of Glucose Disposal Rate Changes and the Onset of Cardiovascular Disease in Patients with Stages 0–3 of Cardiovascular–Kidney–Metabolic Syndrome: A Prospective Cohort Analysis from China
At a Glance
Category
Detail
Condition
Cardiovascular–Kidney–Metabolic Syndrome (CKM) as defined by AHA 2023.
Key Mechanisms
Target Population
Care Setting
Key Highlights
eGDR is a more accessible surrogate marker for insulin resistance compared to HOMA-IR, with implications for clinical practice.
Guideline-Based Recommendations
Diagnosis
Management
Focus on early intervention strategies, such as lifestyle modifications and pharmacotherapy, to prevent CVD events in CKM patients.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults aged 45 and older with CKM stages 0–3 in China.
Emphasize the importance of monitoring insulin resistance and cardiovascular risk.
Clinical Best Practices
Integrate biomarkers such as serum creatinine, lipid profiles, and inflammatory markers for comprehensive risk evaluation.
Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.
